Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 7 | 2 |
| 2 Introduction | 9 | 21 |
| 2.1 Disease Introduction | 9 | 1 |
| 2.2 Epidemiology | 9 | 1 |
| 2.3 Symptoms | 10 | 1 |
| 2.4 Etiology and Pathophysiology | 10 | 1 |
| 2.5 Diagnosis | 11 | 1 |
| 2.6 Classification | 12 | 1 |
| 2.7 Treatment Guidelines and Options | 13 | 3 |
| 2.7.1 ICS Monotherapy for the Maintenance Treatment of Asthma | 16 | 1 |
| 2.7.1.1 Arnuity (fluticasone furoate) as First-line Maintenance Therapy | 16 | 2 |
| 2.7.1.2 Arnuity (fluticasone furoate) versus fluticasone propionate as First-line Maintenance Therapy | 18 | 1 |
| 2.7.2 Montelukast sodium as First-Line Maintenance Therapy | 19 | 1 |
| 2.7.2.1 Montelukast sodium | 19 | 1 |
| 2.7.3 ICS/LABA Combination Therapy | 20 | 1 |
| 2.7.3.1 Seretide (fluticasone propionate and salmeterol xinafoate) as a Second-Line Maintenance Therapy | 20 | 1 |
| 2.7.3.2 Symbicort (budesonide and formoterol fumarate) as Second-Line Maintenance Therapy | 21 | 1 |
| 2.7.3.3 Symbicort (budesonide and formoterol fumarate) versus Advair (fluticasone propionate and salmeterol xinafoate) as Second-line Maintenance Therapy | 22 | 2 |
| 2.7.3.4 Formost/Evocort (mometasone furoate and formoterol fumarate) as Second-Line Maintenance Therapy | 24 | 1 |
| 2.7.3.5 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) versus Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) as Second-Line Maintenance Therapy | 24 | 1 |
| 2.7.4 Add-on Therapies | 25 | 1 |
| 2.7.4.1 Xolair (omalizumab) as Maintenance Add-on Therapy | 25 | 2 |
| 2.7.4.2 Montelukast sodium as Maintenance Add-on Therapy | 27 | 1 |
| 2.7.4.3 Spiriva (tiotropium bromide) as Maintenance Add-on Therapy | 28 | 2 |
| 3 Marketed Products | 30 | 11 |
| 3.1 Overview | 30 | 1 |
| 3.2 ICS for the Maintenance Treatment of Asthma | 30 | 1 |
| 3.2.1 Arnuity (fluticasone furoate) | 30 | 1 |
| 3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma | 31 | 1 |
| 3.3.1 Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) 21TGlaxoSmithKline | 31 | 1 |
| 3.3.2 Symbicort (budesonide and formoterol fumarate) AstraZeneca, Co-Promotion with Astellas Pharma | 32 | 1 |
| 3.3.3 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) GlaxoSmithKline | 33 | 1 |
| 3.3.4 Flutiform (fluticasone propionate and formoterol fumarate) SkyePharma | 34 | 1 |
| 3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma | 35 | 1 |
| 3.4.1 Xolair (omalizumab) Novartis and Genentech | 35 | 1 |
| 3.4.2 Montelukast sodium | 36 | 1 |
| 3.4.3 Spiriva (tiotropium bromide) Boehringer Ingelheim | 37 | 1 |
| 3.5 Comparative Efficacy and Safety of Marketed Products | 38 | 3 |
| 4 Pipeline Analysis | 41 | 21 |
| 4.1 Overview | 41 | 1 |
| 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type | 41 | 2 |
| 4.3 Pipeline by Molecular Target | 43 | 4 |
| 4.4 Promising Pipeline Molecules | 47 | 1 |
| 4.4.1 Mepolizumab 50T 50T GlaxoSmithKline | 47 | 2 |
| 4.4.2 Reslizumab Teva Pharmaceutical | 49 | 2 |
| 4.4.3 Lebrikizumab Roche/Genentech | 51 | 1 |
| 4.4.4 Dupilumab 50T 50T Regeneron Pharmaceuticals in Collaboration with Sanofi | 52 | 3 |
| 4.4.5 Tralokinumab 50T 50T AstraZeneca | 55 | 1 |
| 4.4.6 Benralizumab 50T 50T AstraZeneca | 56 | 2 |
| 4.5 Comparative Efficacy and Safety of Pipeline Products | 58 | 4 |
| 5 Clinical Trial Analysis | 62 | 10 |
| 5.1 Failure Rate | 62 | 1 |
| 5.1.1 Overall Failure Rate | 62 | 1 |
| 5.1.2 Failure Rate by Phase and Molecule Type | 63 | 1 |
| 5.1.3 Failure Rate by Phase and Molecular Target | 64 | 1 |
| 5.2 Clinical Trial Size | 65 | 1 |
| 5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target | 65 | 2 |
| 5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target | 67 | 2 |
| 5.3 Clinical Trial Duration | 69 | 1 |
| 5.3.1 Trial Duration by Stage of Development by Molecule Type and Molecular Target | 69 | 1 |
| 5.4 Summary of Clinical Trial Metrics | 70 | 2 |
| 6 Multi-Scenario Forecast | 72 | 18 |
| 6.1 Geographical Markets | 72 | 1 |
| 6.2 Asia-Pacific Market | 73 | 2 |
| 6.3 India | 75 | 1 |
| 6.3.1 Treatment Usage Patterns | 75 | 1 |
| 6.3.2 Annual Cost of Therapy | 76 | 1 |
| 6.3.3 Market Size | 76 | 1 |
| 6.4 China | 77 | 1 |
| 6.4.1 Treatment Usage Patterns | 77 | 1 |
| 6.4.2 Annual Cost of Therapy | 78 | 1 |
| 6.4.3 Market Size | 79 | 1 |
| 6.5 Australia | 80 | 1 |
| 6.5.1 Treatment Usage Patterns | 80 | 1 |
| 6.5.2 Annual Cost of Therapy | 81 | 1 |
| 6.5.3 Market Size | 82 | 1 |
| 6.6 South Korea | 83 | 1 |
| 6.6.1 Treatment Usage Patterns | 83 | 1 |
| 6.6.2 Annual Cost of Therapy | 84 | 1 |
| 6.6.3 Market Size | 85 | 1 |
| 6.7 Japan | 86 | 1 |
| 6.7.1 Treatment Usage Patterns | 86 | 1 |
| 6.7.2 Annual Cost of Therapy | 87 | 1 |
| 6.7.3 Market Size | 88 | 2 |
| 7 Drivers and Barriers | 90 | 2 |
| 7.1 Drivers | 90 | 1 |
| 7.1.1 Rising Prevalence | 90 | 1 |
| 7.1.2 New Costly Market Entries | 90 | 1 |
| 7.1.3 Growing Alternative Therapeutic Choices | 90 | 1 |
| 7.2 Barriers | 90 | 1 |
| 7.2.1 Usage of Traditional Medicines | 90 | 1 |
| 7.2.2 Treatment Regimen Adherence | 91 | 1 |
| 7.2.3 Limited Understanding of Underlying Causes | 91 | 1 |
| 7.2.4 Lack of Awareness and Affordability of High-Cost Biological Products | 91 | 1 |
| 8 Deals and Strategic Consolidations | 92 | 14 |
| 8.1 Co-development Deals | 92 | 1 |
| 8.1.1 Deals by Region and Value | 92 | 1 |
| 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value | 93 | 1 |
| 8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target | 94 | 3 |
| 8.1.4 Key Co-Development Deals | 97 | 1 |
| 8.1.4.1 Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide | 97 | 1 |
| 8.1.4.2 Five Prime Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline | 97 | 1 |
| 8.1.4.3 DBV Technologies Exercises Option for R&D Agreement with Stallergenes for Birch Allergy Treatment | 98 | 1 |
| 8.1.4.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies | 98 | 1 |
| 8.2 Licensing Deals | 99 | 1 |
| 8.2.1 Deals by Region and Value | 99 | 1 |
| 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value | 100 | 1 |
| 8.2.3 Deal Value by Stage of Development, Molecule Type and Molecular Target | 100 | 3 |
| 8.2.4 Key Licensing Deals | 103 | 1 |
| 8.2.4.1 AstraZeneca Extends Research and Licensing Agreement with Dynavax Technologies | 103 | 1 |
| 8.2.4.2 AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 | 104 | 1 |
| 8.2.4.3 MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca 50T 50T Terminated | 104 | 1 |
| 8.2.4.4 Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals Terminated | 104 | 1 |
| 8.2.4.5 ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs | 105 | 1 |
| 9 Appendix | 106 | 25 |
| 9.1 All Pipeline Drugs by Phase of Development | 106 | 11 |
| 9.1.1 Discovery | 106 | 1 |
| 9.1.2 Preclinical | 107 | 5 |
| 9.1.3 Phase I | 112 | 1 |
| 9.1.4 Phase II | 113 | 2 |
| 9.1.5 Phase III | 115 | 1 |
| 9.1.6 Pre-registration | 116 | 1 |
| 9.2 Summary of Multi-Scenario Market Forecasts to 2021 | 116 | 4 |
| 9.2.1 Asia-Pacific | 116 | 1 |
| 9.2.2 China | 117 | 1 |
| 9.2.3 India | 117 | 1 |
| 9.2.4 Australia | 118 | 1 |
| 9.2.5 South Korea | 118 | 1 |
| 9.2.6 Japan | 119 | 1 |
| 9.3 References | 119 | 5 |
| 9.4 Abbreviations | 124 | 2 |
| 9.5 Research Methodology | 126 | 5 |
| 9.5.1 Secondary Research | 127 | 1 |
| 9.5.2 Marketed Product Profiles | 127 | 1 |
| 9.5.3 Late-Stage Pipeline Candidates | 127 | 1 |
| 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products | 128 | 1 |
| 9.5.5 Product Competitiveness Framework | 128 | 1 |
| 9.5.6 Pipeline Analysis | 128 | 1 |
| 9.5.6.1 Overall Pipeline | 128 | 1 |
| 9.5.6.2 Clinical Trials | 128 | 1 |
| 9.5.6.2.1 Failure Rate | 128 | 1 |
| 9.5.6.2.2 Clinical Trial Size | 128 | 1 |
| 9.5.6.2.3 Clinical Trial Duration | 129 | 1 |
| 9.5.6.2.4 Clinical trial Endpoint Analysis | 129 | 1 |
| 9.5.7 Forecasting Model | 129 | 1 |
| 9.5.8 Deals Data Analysis | 130 | 1 |
| 9.6 Contact Us | 130 | 1 |
| 9.7 Disclaimer | 130 | 1 |
